Key clinical point: A network meta-analysis suggests that relugolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, had similar efficacy and safety to parenteral degarelix.
Major finding: Compared with GnRH agonists, there was no significant difference in castration rate at 12 months with relugolix (risk ratio [RR], 1.09; 95% credible interval [CrI], 0.95-1.23) and degarelix (RR, 0.98; 95% CrI, 0.91-1.06). Efficacy ranking analyses showed that relugolix was the most effective medical castration drug to induce sustained castration at 12 months. Compared with GnRH agonists, adverse events rates were similar with relugolix (RR, 0.99; 95% CrI, 0.6-1.6) and degarelix (RR, 1.1; 95% CrI, 0.75-1.35).
Study design: A network meta-analysis of 4 studies compared relugolix and degarelix with GnRH antagonists in 2,059 patients with advanced prostate cancer.
Disclosures: The study did not receive any funding. The authors declared no competing interest.
Source: Motlagh RS et al. Eur Urol Oncol. 2021 Jul 20 . doi: 10.1016/j.euo.2021.07.002 .